The diagnostic performance of copeptin in clinical practice: A prospective study
Authors' conclusion
Copeptin >4.0 pmol/L after an overnight WDT can be used to rule out cDI and copeptin ≥21 pmol/L at baseline to diagnose nDI. The diagnostic performance of copeptin in the context of the WDT is otherwise limited in the diagnostic work-up of patients with polyuria-polydipsia syndrome.
Study context
- Population
- Patients with polyuria-polydipsia syndrome evaluated with a water deprivation test (WDT)57 women
- Participants
- 88 patients
- Comparison
- Plasma copeptin during WDT across central diabetes insipidus (cDI), nephrogenic DI (nDI) and primary polydipsia (PP)
- cDIn = 21
- nDIn = 5
- PPn = 62
- Outcome
- Diagnostic performance of copeptin
Methodological detailswater deprivation test
- Water deprivation test
Performance
As reported in the abstract
Copeptin at baseline
- Highest copeptin in cDI after 8 h of WDT
- 4.0 pmol/L
Further findings
- PP with urine osmolality <600 mOsm/kg: copeptin >4.0 pmol/L after WDT
- 17% · 7
- PP with urine osmolality ≥600 mOsm/kg: copeptin >4.0 pmol/L after WDT
- 67% · 14
- PP with urine osmolality <600 mOsm/kg: copeptin >4.0 pmol/L after WDT: 41 PP patients with urine osmolality <600 mOsm/kg
- PP with urine osmolality ≥600 mOsm/kg: copeptin >4.0 pmol/L after WDT: 21 PP patients with urine osmolality ≥600 mOsm/kg
Original publication
The diagnostic performance of copeptin in clinical practice: A prospective study. Clin Endocrinol (Oxf). Published 30 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →